WHO and UN actions undermine IP and hurt innovation, warns PhRMA
18-03-2019
PhRMA urges USTR to protect US innovation abroad
13-02-2017
BIO welcomes ‘Special 301 Report’
29-04-2016
golden_brown / iStockphoto.com
Trade associations Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organization (BIO) have called for Malaysia to be placed on the US Trade Representative’s (USTR) watch list in its “2018 Special 301 Report”.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PhRMA, BIO, USTR, innovation, patent, Special 301 Report, medicines, IP protection, market access, barriers, biopharmaceuticals
